GlassScriptPhysician profile
Victoria Chamblee Collier
NPI 1396308094
$4,156.05
in general payments reported to CMS, 2019-2025
22 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $690 · 2024: $1,719 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,976 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,976.07 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.54 | 2023-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $601.66 | 2023-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $470.08 | 2024-2025 | |
| Janssen Biotech, INC. | $347.82 | 2023-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $325.76 | 2023-2025 | |
| Lilly USA, LLC | $287.82 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $264.31 | 2023-2025 | |
| Incyte Corporation | $186.99 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $167.43 | 2024-2025 | Nemluvio |
| Ucb, INC. | $162.56 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $157.80 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $127.82 | 2023-2025 | Sotyktu |
| Pfizer INC. | $100.37 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $76.77 | 2024-2025 | Acthar |
| Almirall LLC | $52.89 | 2023-2025 | Seysara |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $47.27 | 2024-2025 | Daxxify |
| Verrica Pharmaceuticals INC. | $38.67 | 2023-2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $34.07 | 2025 | Zoryve |
| Mayne Pharma Commercial LLC | $34.06 | 2025 | |
| Dermavant Sciences, INC. | $30.48 | 2024 | Vtama |
| Biofrontera INC. | $20.79 | 2025 | |
| Organon LLC | $8.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.